CD33 CAR T for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune therapy called CAR T cells that target the CD33 protein on leukemia cells. It is for people with AML that has returned or not gone away after standard treatments, and who have a stem cell donor available for a transplant afterward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that has come back or not responded to treatment.
- Your cancer cells have a protein called CD33 on them (your doctor will test for this).
- You are between 1 and 70 years old.
- You have a stem cell donor ready for a transplant after this treatment.
- You are in fairly good health (able to do daily activities) and expected to live at least 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
This early-phase study tests a customized immune-cell therapy (CAR-T) made from your own T cells to treat acute myeloid leukemia (AML) that has the marker CD123. It may help shrink the leukemia and improve long-term control, but the treatment is still being tested for safety and early effectiveness.
This trial tests a new type of immune cell therapy (called CAR-T) designed to target and fight acute myeloid leukemia (AML) that has come back or didn't respond to standard treatments. The therapy uses your own immune cells, modified in the lab to recognize and kill leukemia cells.
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Hear when a new Refractory/Relapsed Acute Myeloid Leukaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.